Induction of apoptosis by the bis-Pt(III) complex [Pt2(2-mercaptopyrimidine)4Cl2]

被引:24
作者
González, VM
Fuertes, MA
Pérez-Alvarez, MJ
Cervantes, G
Moreno, V
Alonso, C
Pérez, JM
机构
[1] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
[2] Univ Barcelona, Dept Quim Inorgan, E-08028 Barcelona, Spain
关键词
p53; apoptosis; cytotoxicity; cisplatin; Pt-2(2-mercaptopyrimidine)(4)Cl-2;
D O I
10.1016/S0006-2952(00)00329-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We analyzed both the cytotoxicity and the type of cell death produced by the novel binuclear Pt(III) compound Pt-Spym ([Pt-2(2-mercaptopyrimidine)(4)Cl-2]) in kidney human fibroblasts and in human tumor cell lines (HeLa, CH1, CH1cisR and HL-60). The data showed that Pt-Spym displayed higher cytotoxicity against these tumor cells than cisplatin. In contrast, Pt-Spym had low toxicity against normal human fibroblasts. Interestingly, Pt-Spym circumvented cisplatin resistance in CH1cisR cells. We also observed that Pt-Spym induced the characteristic changes attributed to apoptosis in cells with normal levels of p53 protein (CH1 and CH1cisR) and with low levels of p53 protein (HeLa), but not in cells lacking p53 (HL-60). Interestingly, Western blot data indicated that apoptosis induction by Pt-Spym in HeLa, CH1, and CH1cisR cells was not associated with drastic changes in p53 levels. However, cis-DDP strongly decreased p53 levels in CH1 and CH1cisR cells and abolish p53 protein in HeLa cells. Altogether, these results suggest that induction of apoptosis by Pt-Spym requires the presence of p53 protein. BIOCHEM PHARMACOL 60;3:371-379, 2000. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:371 / 379
页数:9
相关论文
共 31 条
[1]  
ALLEY MC, 1988, CANCER RES, V48, P589
[2]  
CERVANTES G, 1997, METAL BASED DRUGS, V4, P7
[3]  
CHABNER BA, 1989, CANCER PRINCIPLES PR, P349
[4]   CLONAL P53 MUTATION IN PRIMARY CERVICAL-CANCER - ASSOCIATION WITH HUMAN-PAPILLOMAVIRUS-NEGATIVE TUMORS [J].
CROOK, T ;
WREDE, D ;
TIDY, JA ;
MASON, WP ;
EVANS, DJ ;
VOUSDEN, KH .
LANCET, 1992, 339 (8801) :1070-1073
[5]  
Dabholkar M, 1996, Cancer Chemother Biol Response Modif, V16, P88
[6]  
DIVE C, 1993, FRONTIERS PHARM CANC, P21
[7]  
EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275
[8]   MECHANISMS AND FUNCTIONS OF CELL-DEATH [J].
ELLIS, RE ;
YUAN, JY ;
HORVITZ, HR .
ANNUAL REVIEW OF CELL BIOLOGY, 1991, 7 :663-698
[9]  
FRITSCHE M, 1993, ONCOGENE, V8, P307
[10]  
Gallagher WM, 1997, ONCOGENE, V14, P185